Eton Pharmaceuticals Inc. (ETON) Misses Q4 EPS by 5c

Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q4 EPS of ($0.09), $0.05 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $7.7 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
• Citi upgrades C.H. Robinson to Buy with $185 target, Opens 90-Day upside catalyst watch